Timothy Schroeder

Provides clinical research and consulting services

Engages in discovering and developing drugs for curing cancer

Functions as a College/University

The private company is based in Covington, KY. One NKY Alliance, Inc., doing business as OneNKY Alliance, is a community-focused organization dedicated to transforming Northern Kentucky—specifically Boone, Campbell, and Kenton counties—by uniting and mobilizing leaders to drive measurable progress in unity, health, and education. The alliance serves a population of approximately 400,000 across 37 cities and fosters a shared regional vision to elevate quality of life and economic vitality through collaborative initiatives. Key programs include OneNKY Unity, which promotes a unified community identity; OneNKY Health, focusing on systemic policy and infrastructure improvements such as the Breathe Easy NKY coalition advocating for comprehensive smoke-free ordinances and the OneNKY Connector Trail, a 31-mile cross-jurisdictional trail encouraging active lifestyles; and EducateNKY, aimed at enhancing educational opportunities and student outcomes. The alliance also leads leadership development through LaunchNKY and economic growth efforts via the Corridor of Commerce. The organization operates from Covington, KY, and is a central partner in the OneNKY Center—a collaborative hub housing multiple regional growth organizations to advance economic development, innovation, tourism, and community enhancement. Additionally, OneNKY Frankfort serves as a strategic advocacy and collaboration space near the state capitol to unify Northern Kentucky’s voice in state government. The CEO of the company is Karen Finan.

Nora's Gift Foundation, Inc. is a 501(c)(3) nonprofit organization dedicated to supporting patients with end-stage solid organ failure and their families. The non-profit company is based in Houston, TX. The foundation operates Nora’s Home near the Texas Medical Center, providing affordable, home-like accommodations and comprehensive support services for transplant patients—including those undergoing heart, kidney, liver, lung, pancreas, intestine, and LVAD treatments—and their families. Nora’s Home offers amenities such as communal kitchens, fitness and meditation rooms, healing gardens, transportation shuttles, and social support programs like buddy mentorship and educational resources. The foundation ensures no guest is turned away due to financial hardship through initiatives like the adopt-a-family program, funded by annual fundraising events. Nora’s Gift Foundation also provides transplant-related educational materials and fosters community involvement through volunteering and donor recognition programs. The company was founded in 1998 by A. Osama Gaber, Lillian Gaber.

Operates as a diagnostic laboratory

Lepton Pharmaceuticals Ltd. is an Israeli biotechnology company specializing in the development of RNA-based therapeutics that leverage small non-coding RNAs, such as siRNA and miRNA, to regulate gene expression for treating serious diseases with unmet medical needs. The company is based in Zichron Yakov, Israel. The company’s proprietary CASTLING technology (LN-CAST) is a gene editing platform that modulates microRNA expression to enhance the efficacy and durability of cell-based therapies, particularly adoptive T cell immunotherapy for cancer. This technology targets multiple genes and biological pathways by inserting beneficial pre-miRNA sequences into harmful gene loci, reversing pathological gene expression patterns. The LN-CAST platform is applicable to various cell types, including CAR-T, CAR-NK, and stem cells. Lepton’s siRNA program focuses on LN-008, a chemically modified siRNA drug candidate targeting the MASP2 gene, which is involved in autoimmune kidney diseases such as IgA nephropathy and lupus nephritis. LN-008 is designed for liver-specific delivery via GalNAc conjugation, enabling infrequent subcutaneous dosing with high knockdown efficiency and a favorable safety profile. The program builds on clinical proof of concept from MASP2-neutralizing antibodies and aims to address additional indications like ischemia-reperfusion injury and inflammatory vascular diseases. The company integrates advanced RNA interference mechanisms, chemical modifications, and delivery technologies to develop potent, specific, and safe RNAi therapeutics. Lepton holds US patent applications protecting its technologies and drug candidates and collaborates with external partners to advance its research.

Engages in developing new medicines and therapies to improve mental health & neurological disorders